Kevin Fischbeck
BofA Securities, Research Division

It's my pleasure to be hosting the meeting with DaVita. We have Joel Ackerman, who's the CFO of the company; as well as Nic Eliason, who's Vice President of Capital Markets and Investor Relations. I think we're going to jump right in if you you're good with that. All right. Excellent.

Kevin Fischbeck
BofA Securities, Research Division

So I know your favorite topic is volumes. So maybe we should start with volumes.

Joel Ackerman
CFO & Treasurer

Sounds good.

Kevin Fischbeck
BofA Securities, Research Division

So I guess Q1 incremental treatment guidance was raised from flat to kind of up, call it, 25, 50 basis points. What drove the increase there? And how confident are you in the durability of that improvement?

Joel Ackerman
CFO & Treasurer

Sure. So first, good afternoon, everyone, and thanks for having us, Kevin. So we really divided the increase in the guide into 2 buckets.

First is increased census from Fresenius clinic closures. They have announced the closing of about 100 clinics, and we expect to get our fair share of the patients that they don't retain. So that would be about half the volume increase.

The second is just what we observed during Q1, our treatment volume came in about 20 basis points better than expected, largely as a result of census being ahead of plan, and we expect that to continue. You can look across all the different inputs and tweak any one of them. The one I'd highlight is that really came in above plan was mortality. As you know, mortality has been elevated